RWMFX
Price
$68.79
Change
+$0.27 (+0.39%)
Updated
Jun 2 closing price
Net Assets
214.46B
TAGRX
Price
$67.72
Change
-$0.58 (-0.85%)
Updated
Jun 2 closing price
Net Assets
6.35B
Interact to see
Advertisement

RWMFX vs TAGRX

Header iconRWMFX vs TAGRX Comparison
Open Charts RWMFX vs TAGRXBanner chart's image
RWMFX vs TAGRX Comparison Chart in %
View a ticker or compare two or three
VS
RWMFX vs. TAGRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RWMFX is a Hold and TAGRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RWMFX has more cash in the bank: 214B vs. TAGRX (6.36B). RWMFX pays higher dividends than TAGRX: RWMFX (1.40) vs TAGRX (0.22). RWMFX was incepted earlier than TAGRX: RWMFX (24 years) vs TAGRX (42 years). TAGRX (1.02) is less costly to investors than RWMFX (0.31). TAGRX is a more actively managed with annual turnover of: 49.00 vs. RWMFX (29.00). RWMFX has a lower initial minimum investment than TAGRX: RWMFX (250) vs TAGRX (1000). RWMFX annual gain was more profitable for investors over the last year : 7.92 vs. TAGRX (5.42). RWMFX return over 5 years is better than : 26.49 vs. TAGRX (-1.14).
RWMFXTAGRXRWMFX / TAGRX
Total Expense Ratio0.311.0131%
Annual Report Gross Expense Ratio0.311.0230%
Fund Existence24 years42 years-
Gain YTD5.9914.132145%
Front LoadN/A5%-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets214B6.36B3,367%
Annual Yield % from dividends1.400.22627%
Returns for 1 year7.925.42146%
Returns for 3 years33.6417.86188%
Returns for 5 years26.49-1.14-2,315%
Returns for 10 years86.1569.26124%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NAK2.380.09
+3.93%
Northern Dynasty Minerals Ltd
FNB17.380.28
+1.64%
FNB Corp
MO69.240.59
+0.86%
Altria Group
PMEC0.78N/A
-0.24%
Primech Holdings Ltd
PRLD3.51-0.31
-8.12%
Prelude Therapeutics